ZEMAIRA® Alpha-1 Proteinase Inhibitor (Human) Update

“Our industry partners at CSL Behring are keeping in close contact with us regarding updates for the Alpha-1 community. The Alpha-1 Foundation is committed to providing direct communication and timely information to you as soon as we receive it from leadership.”- Scott Santarella, Alpha-1 Foundation President & CEO

January 28, 2022 – At CSL Behring, we remain fully committed to manufacturing adequate supply of ZEMAIRA to meet the needs of the Alpha-1 community.

As part of our efforts to meet present and future demand for ZEMAIRA supply, CSL Behring entered a strategic partnership with Thermo Fisher. We expect additional product availability from Thermo Fisher pending final approval from regulatory authorities. However, until we receive this regulatory approval, ZEMAIRA supplies will continue to be allocated for existing patients. We are continuing to work with the FDA and are dedicated to increasing supply as quickly as possible. We will provide an update as more information on regulatory approvals becomes available.

Existing ZEMAIRA patients are encouraged to contact their pharmacy regarding their individual prescription and their physician about any changes to their treatment plan and alternative therapy options if necessary. To be notified about updates on ZEMAIRA supplies, Alpha-1 patients can enroll in ZEMAIRA Connect by calling 1-866-ZEMAIRA (1-866-936-2472) to talk with a Case Manager from 8AM to 8PM ET. For additional Healthcare Provider questions on ZEMAIRA supplies, please contact your ZEMAIRA Representative at 1-855-ZEMAIRA (855-936-2472) or email at ZEMAIRASupport@CSLBehringSales.com.